Two experts from Cerevance discussed data from the company’s posters recently presented at AAIC 2025, which highlighted potential therapeutic targets for Alzheimer disease. [WATCH TIME: 5 minutes]
Mark Carlton, PhD
Advertisement
Articles by Mark Carlton, PhD
Advertisement
Latest Updated Articles
Advancing Neurodegenerative Disease Research With Innovative Targets and Platforms: Xiao Xu, PhD; Mark Carlton, PhDPublished: August 7th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CALLIPER Subpopulation Data Support Therapeutic Effect of Vidofludimus Calcium in Primary Progressive MS
2
Phase 3 Topline Results Show Rituximab Noninferior to Cladribine in Reducing New or Enlarging Brain Lesions in Relapsing-Remitting MS
3
Phase 2a INFORM-MS Trial to Study Anti-CD3 Agent Foralumab in Nonactive Secondary Progressive MS
4
Leveraging Artificial Intelligence to Extract Real-World Insights in Multiple Sclerosis: Rebekah Foster, MBA, and John Foley, MD, FAAN
5
